In the news / Drug Delivery

NEWS
A group of UAHS researchers including BIO5 members Drs. Rick Schnellmann, Roberta Brinton, Todd Vanderah, Monica Kraft, Scott Boitano, Andrew Capaldi, Michael Worobey, Louise Hecker, and Julie Ledford participated in the “Discovering New Medicines in Arizona” one-day summit, hosted by the AZ Center for Drug Discovery and the UA Cancer Center. The event sought to highlight key areas of research that seek to treat diseases prevalent in Arizona while establishing collaborations that enable success for future research and discoveries.
NEWS
Leading experts including UA Pharmacology and Toxicology assistant professor and BIO5 member Dr. Jun Wang, say understanding how the influenza virus replicates inside the body helps researchers develop a wider range of antiviral drugs. After finding medication resistant mutations within multiple flu viruses, Dr. Wang and other research teams across the globe, are looking to develop new drugs to target them.
NEWS
Dr. Irving Kron, a BIO5 member, professor of surgery with the UA College of Medicine - Tucson, and senior associate vice president for UA Health Sciences, has been named the new contact principal investigator (PI) for the UA Health Sciences and Banner Health 'All of Us' research program and precision medicine initiative. In his new role, Dr. Kron will lead the multiple UA and Banner Health established PI leadership teams, which include a team led by fellow BIO5 member Dr. Eric Reiman.
NEWS
A team led by The BIO5 Institute's Roberta Diaz Brinton, PhD, director of the Center for Innovation in Brain Science, received the multi-million dollar grant from the National Institute on Aging. The five-year grant will fund a national multi-site Phase 2 clinical trial to determine the effectiveness of allopregnanalone, or allo, as a treatment for individuals with early-stage Alzheimer’s who carry the genetic risk factor for the disease. This award supports the goals of the National Alzheimer’s Project Act.
NEWS
Most studies have shown correlations between the microbiome and the effectiveness of drugs, but a recent study is one of the first to dig into how these associations work. Better understanding the causal links in drug responses may mean scientists are able to do more with our gut microbes.  BIO5 faculty and UA College of Medicine-Phoenix associate professor Dr. Melissa Herbst-Kralovetz, thinks this may pave the way for doctors to choose the most effective drug for individual patients.
NEWS
BIO5 member Dr. Michael Johnson, Assistant Professor of Immunobiology in the UA College of Medicine – Tucson, is using a five-year, $1.9 million grant from the National Institute of General Medical Sciences to explore whether copper could be the cornerstone for the next generation of antibiotics.
NEWS
Tucson-based drug startup Cancer Prevention Pharmaceuticals Inc. has announced the launch of a Phase 2 clinical trial at Vanderbilt University Medical Center to test the company’s flagship drug candidate for preventing gastric cancer. The company was co-founded by BIO5 Institute member and Cancer Center member Dr. Eugene Gerner.